Nath Bio-Genes Schedules May 5 Earnings Call for FY25 Performance Review

Nath Bio-Genes (India) Ltd has announced its upcoming earnings conference call, scheduled for Tuesday, May 5, 2026, at 4:00 PM IST. This call is key for investors to understand FY25 performance and outlook, with margin pressures expected to be a primary focus.

Earnings Call Announcement

Nath Bio-Genes (India) Ltd has officially announced its upcoming earnings conference call. The call is set for 4:00 PM Indian Standard Time (IST) on Tuesday, May 5, 2026. This announcement is important for investors monitoring the company's financial health.

Investor Insights and Board Approvals

Earnings calls are key events where management shares detailed insights into financial results, strategic moves, and future plans. These calls allow investors and analysts to assess performance, understand business drivers, and address concerns. For Nath Bio-Genes, the call follows a board meeting on May 4th to approve audited results and a final dividend.

Company Overview and Financial Trends

Nath Bio-Genes, established in 1979, is a long-standing company in India's agri-tech sector, with over four decades of operation. The company develops, produces, and sells hybrid and GM seeds for various crops and vegetables, along with plant nutrition supplements. It has expanded its offerings beyond cotton seeds to include paddy, maize, and vegetable seeds, aiming for profitable growth and international expansion via a joint venture in Uzbekistan.

Recent financials show revenue growth, with Q3 FY26 revenues up 79% year-on-year to ₹660 million and nine-month FY26 revenues increasing 23% year-on-year. Net profit for FY25 reached ₹42 crore (a 4.9% YoY rise), and Q3 FY26 net profit surged 172.3% year-on-year to ₹7 crore. However, the company experienced squeezed EBITDA margins in Q3 FY26. Elevated inventories and increased finance costs point to high working capital needs.

Analyst Ratings and Financial Concerns

MarketsMojo rated Nath Bio-Genes a 'Sell' on April 7, 2026, with a Mojo Score of 31.0, indicating below-average investment appeal. Recent quarterly results for December 2025 showed a pre-tax loss of ₹1.95 crore and an after-tax loss of ₹0.15 crore, raising concerns about liquidity. The stock has lagged the S&P BSE 100 Index by -3.46% in the past year, and the company's three-year return on equity stands at a low 6.22%.

Market Competition

Nath Bio-Genes competes with major companies such as Mahyco, Syngenta Group, UPL Ltd (Advanta Seeds), Kaveri Seed Company, and Bayer CropScience. These competitors also emphasize R&D and portfolio expansion in India's active seed market.

Key Discussion Points for Investors

Investors will listen for management commentary on margin performance and strategies to manage working capital. Attention will be on the outlook for key segments including paddy, maize, and vegetables. Guidance on international expansion and new product pipeline performance will also be important.